Celldex Therapeutics, Inc. (CLDX) Return on equity 2016–2025
Celldex Therapeutics, Inc. (CLDX) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-49.1%FY2025 · since FY2016: -48.4% → -49.1%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -49.1% | -28.0 pp |
| FY2024 | -21.1% | +11.8 pp |
| FY2023 | -33.0% | +1.5 pp |
| FY2022 | -34.4% | -17.6 pp |
| FY2021 | -16.8% | +11.7 pp |
| FY2020 | -28.6% | +25.6 pp |
| FY2019 | -54.1% | +67.8 pp |
| FY2018 | -121.9% | -82.5 pp |
| FY2017 | -39.4% | +9.1 pp |
| FY2016 | -48.4% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More CLDX financial trends
CLDX RevenueCLDX Net incomeCLDX Net marginCLDX Gross profitCLDX Gross marginCLDX Operating incomeCLDX Operating marginCLDX Operating cash flowCLDX Free cash flowCLDX Capital expendituresCLDX Stock buybacksCLDX Dividends paidCLDX Total assetsCLDX Total liabilitiesCLDX Shareholders’ equityCLDX overview →